EQT (NYSE: EQT - Get Free Report) and Global Partners (NYSE: GLP - Get Free Report) are both energy companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings and Valuation This table compares EQT and Global
MichaelAaron Flicker, founder and CEO of XenoPsi Ventures, walks through the impact that GLP-1 drugs are having on consumer behavior and how some of the top consumer food brands are responding. Flicker examines how GLP-1 users impact the behavior of entire households, the changing dynamic of the restaurant experience and where GLP-1 users are spending outside of grocery stores and eating out.
Bank of America Corp DE acquired a new position in shares of Global Partners LP (NYSE: GLP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 36,399 shares of the energy company's stock, valued at approximately $264,000. Bank of America Corp
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs. A new slate of injections, pills, and combination regimens target the amylin pathway, which involves a hormone released in the pancreas alongside insulin that helps regulate hunger and fullness.
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in people living with obesity.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare systems INDIANAPOLIS, Oct. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem.
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death vs. insulin glargine, suggesting the potential for more comprehensive health benefits INDIANAPOLIS, Sept.
Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) says new analysis of its ketamine-based alcohol treatment shows patients cut heavy drinking days by 67% compared with placebo, more than four months after their last dose. The company says that puts SVN-001 ahead of naltrexone, sold as Vivitrol, and the GLP-1 drugs semaglutide and pemvidutide on the same measure.
Eli Lilly's high valuation could limit the stock's future returns. Viking Therapeutics is a much smaller company, and it has a promising GLP-1 asset in VK2735.
